PeriphEx

What PeriphEx does

PeriphEx Corp. is a privately held, Austin-based single-product company that develops and sells NoxyPure Therapeutic Nanobubbles, a topical hydrogel containing over one billion suspended oxygen and carbon dioxide nanobubbles intended to alleviate symptoms of peripheral neuropathy. The proprietary technology relies on vanishing-buoyancy nanobubbles (50–250 nm diameter, typically ~100 nm) that remain stable in distilled water and a skin-friendly hydrogel, enabling transcutaneous oxygen delivery through direct cell oxygenation and increased local blood flow via CO2-mediated signaling. The product is positioned as a drug-free, non-invasive, FDA-classified General Wellness treatment, supported by a 29-patient IRB-approved clinical study showing 62.1% of patients experienced at least 50% pain reduction, compared to 27% for Lyrica and 40% for Gabapentin.

The company's commercial model is direct-to-consumer e-commerce through periphex.com, with kits priced at $99 (promotional $69 via code WELCOME69) and an opt-in subscription program activated by email. Distribution is domestic US only, with no retail partners or third-party marketplaces. Demand is driven by content marketing on the company website, customer testimonials, and referrals from a small group of recommending podiatrists including Dr. Douglas Grimm and Dr. Jeffery LaMour. Target customers are adults suffering from diabetic, pre-diabetic, idiopathic, or chemotherapy-induced peripheral neuropathy, with secondary positioning for plantar fasciitis and tendinopathy.

PeriphEx operates with 1–10 employees and has raised no disclosed institutional capital; the first investor is identified as Dr. David Goldblatt. The leadership team includes founder Dr. Zvi Yaniv (Chairman of the Board, 300+ patents) and Chairman Peter Hurwitz (30+ years medical communications and biopharma board experience). Intellectual property consists of two filed patents and one pending patent covering the NoxyPure application, nanobubble technology, and hydrogel delivery mechanism.

Name

PeriphEx

Legal name

PeriphEX Corp.

Website

https://periphex.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

PeriphEx is an Austin-based, privately held company that sells NoxyPure, a single drug-free topical hydrogel product containing proprietary oxygen and carbon dioxide nanobubbles marketed to diabetic peripheral neuropathy sufferers via direct-to-consumer e-commerce.

Ownership category

akta.pro rank

Product category

Peripheral Neuropathy Treatment

NAICS

Medical Equipment and Supplies Manufacturing (3391), Research and Development in Nanotechnology (541713)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC)

akta.pro secondary industry

Hand & Body Care (Lotions, Creams, Body Oils) (CRADANAC)

Keywords

• Peripheral neuropathy treatment
• Nanobubble therapy
• Topical pain relief
• Diabetic neuropathy care
• Wellness hydrogel product

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Operations, Personnel, Infrastructure

Revenue model

1. Product Sales - NoxyPure Treatment Kits: Direct e-commerce sales of NoxyPure therapeutic nanobubble treatment kits. Each treatment includes 10 pouches for 5 applications with disposable booties and towels. Products are sold as one-time purchases with optional subscription available upon contact.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

PeriphEx develops and sells NoxyPure, a topical therapeutic gel containing over one billion suspended oxygen (O2) and carbon dioxide (CO2) nanobubbles (50–250nm in diameter) in a skin-friendly hydrogel. The product is sold as a home-use treatment kit (pouches plus disposable booties/towels) intended to alleviate symptoms of peripheral neuropathy such as tingling, burning, numbness, and nerve pain. The company is a single-product, direct-to-consumer health/wellness manufacturer.

Product overview

PeriphEx Corp. is a single-product company offering NoxyPure Therapeutic Nanobubbles, a proprietary topical gel technology based on oxygen and carbon dioxide nanobubbles for treating peripheral neuropathy and related extremity conditions. The product is sold as a complete treatment kit containing therapeutic gel pouches and disposable booties. No modular add-ons or platform architecture exist.

Differentiator

Problem solved

Functional benefit

Products and services

• NoxyPure Therapeutic Nanobubbles A topical therapeutic gel containing over one billion suspended O2 and CO2 nanobubbles in a soothing hydrogel. Applied as a 20–30 minute soak of feet or hands every other day for five applications. Sold as treatment kits (10 pouches/5 applications or 6 pouches/3 applications) that include disposable booties and towels. Targeted at adults suffering from peripheral neuropathy (diabetic, pre-diabetic, idiopathic, chemotherapy-induced) seeking a drug-free, non-invasive alternative to prescription medications such as Lyrica or Gabapentin.

Quantifiable outcome

• 62.1% of patients experienced at least 50% pain reduction in clinical study (vs 27% for Lyrica, 40% for Gabapentin)
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Grünenthal / Averitas Pharma (Qutenza): Qutenza is an FDA-approved high-concentration capsaicin topical patch for neuropathic pain including diabetic peripheral neuropathy; a prescription-grade topical directly addressing the same indication via a physician-administered format.
• electroCore: electroCore makes non-invasive vagus nerve stimulation devices (gammaCore) for headache and is increasingly extending neuromodulation into additional pain and neurology indications; a broader non-pharmaceutical device peer addressing chronic pain via electrical stimulation rather than topical oxygen.
• Chattem / Sanofi Consumer Healthcare (Icy Hot, Aspercreme): Chattem's Icy Hot and Aspercreme lines are mass-market topical analgesic brands sold OTC through retail; they share the topical-pain-relief format with NoxyPure but compete in musculoskeletal rather than neuropathic pain and are dosed via patches/creams rather than soaks.
• Pfizer (Lyrica): Lyrica (pregabalin) is the leading FDA-approved oral drug for diabetic peripheral neuropathy and the benchmark NoxyPure explicitly compares against (27% efficacy vs. NoxyPure's 62.1%); a major pharma incumbent treating the same condition via the standard-of-care drug pathway.
• Eli Lilly (Cymbalta): Cymbalta (duloxetine) is one of only two FDA-approved oral drugs for diabetic peripheral neuropathy and another standard-of-care pharmaceutical alternative that NoxyPure positions against as a drug-free, side-effect-free option.

Direct peers

• NeuroMetrix: NeuroMetrix makes Quell, a drug-free wearable TENS device marketed for chronic peripheral neuropathy pain — the most directly comparable non-pharmaceutical alternative to NoxyPure targeting the same diabetic peripheral neuropathy patient with a cash-pay D2C model.

Emerging players

• Bioness: Bioness develops non-invasive and implantable neurostimulation devices used in rehabilitation and chronic pain; partial overlap as a drug-free neurostimulation peer targeting peripheral nervous system conditions through electrophysiology rather than nanobubble oxygenation.
• Vertex Pharmaceuticals: Vertex is developing non-opioid pain therapeutics including NaV1.8 inhibitors for neuropathic pain; comparable as a forward-looking competitor pursuing non-opioid mechanisms for peripheral neuropathy through a different (systemic pharmacological) route.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/periphex-corp

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PeriphEx